HSP90AB1’s effect on hepatocellular carcinoma’s local immune response and prognosis
Abstract
Background: HSP90AB1 (heat shock protein 90 kDa alpha, class B, member 1) helps collapsing proteins, and the restraint of HSP90AB1 is anticipated to successfully illuminate the issue of warm stun reaction of the restraint of HSP90. The fundamental component by which HSP90AB1 influences the neighbourhood-resistant reaction to tumours remains vague. Materials and strategies: This investigation analyzes the impact of HSP90AB1 on the composition and dispersion of safe cell invades inside hepatocellular carcinoma (HCC) tissues. At that point, by examining HSP90AB1-associated immunoregulatory qualities, KDR, MICB, and TNFRSF4 were distinguished as critical supporters. A prognostic show joining these qualities was built, and its exactness was approved by utilizing free datasets from the ICGC and TCGA databases. Results: Our discoveries illustrate that the restraint of HSP90AB1 expanded the penetration of CD8+ T cells and other resistant cell populaces inside HCC tissues. This improved resistant reaction was related to moving forward with a quiet prognosis, proposing a potential restorative procedure for HCC. Conclusion: We propose that focusing on HSP90AB1 may improve the survival results of HCC patients by encouraging safe cell penetration into the tumour microenvironment.
References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
2. Rheinbay E, Nielsen MM, Abascal F, et al. Analyses of non-coding somatic drivers in 2658 cancer whole genomes. Nature. 2020; 578: 102-111.
3. McGlynn KA, Petrick JL, El‐Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73(S1): 4-13. doi: 10.1002/hep.31288
4. Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer. Journal of Hepatology. 2019; 70(5): 999-1007. doi: 10.1016/j.jhep.2019.01.027
5. Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology. 2018; 15(10): 599-616. doi: 10.1038/s41571-018-0073-4
6. Proia DA, Kaufmann GF. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy. Cancer Immunology Research. 2015; 3(6): 583-589. doi: 10.1158/2326-6066.cir-15-0057
7. Miyata Y, Nakamoto H, Neckers L. The Therapeutic Target Hsp90 and Cancer Hallmarks. Current Pharmaceutical Design. 2013; 19(3): 347-365. doi: 10.2174/138161213804143725
8. Haase M, Fitze G. HSP90AB1: Helping the good and the bad. Gene. 2016; 575(2): 171-186. doi: 10.1016/j.gene.2015.08.063
9. Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nature Reviews Cancer. 2010; 10(8): 537-549. doi: 10.1038/nrc2887
10. Khandelwal A, Kent CN, Balch M, et al. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor. Nature Communications. 2018; 9(1). doi: 10.1038/s41467-017-02013-1
11. Tomašič T, Durcik M, Keegan BM, et al. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations. International Journal of Molecular Sciences. 2020; 21(18): 6898. doi: 10.3390/ijms21186898
12. Zavareh RB, Spangenberg SH, Woods A, et al. HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell Chemical Biology. 2021; 28(2): 158-168.e5. doi: 10.1016/j.chembiol.2020.10.005
13. Mbofung RM, McKenzie JA, Malu S, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 2017; 8(1). doi: 10.1038/s41467-017-00449-z
14. Kawabe M, Mandic M, Taylor JL, et al. Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin Enhances EphA2 + Tumor Cell Recognition by Specific CD8+ T Cells. Cancer Research. 2009; 69(17): 6995-7003. doi: 10.1158/0008-5472.can-08-4511
15. Rao A, Taylor JL, Chi-Sabins N, et al. Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells. Cancer Research. 2012; 72(13): 3196-3206. doi: 10.1158/0008-5472.can-12-0538
16. Shimp SK, Chafin CB, Regna NL, et al. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cellular & Molecular Immunology. 2012; 9(3): 255-266. doi: 10.1038/cmi.2012.5
17. Lin CC, Tu CF, Yen MC, et al. Inhibitor of Heat-shock Protein 90 Enhances the Antitumor Effect of DNA Vaccine Targeting Clients of Heat-shock Protein. Molecular Therapy. 2007; 15(2): 404-410. doi: 10.1038/sj.mt.6300014
18. Graner MW. HSP90 and Immune Modulation in Cancer. Hsp90 in Cancer: Beyond the Usual Suspects. 2016: 191-224. doi: 10.1016/bs.acr.2015.10.001
19. Yun TJ, Harning EK, Giza K, et al. EC144, a Synthetic Inhibitor of Heat Shock Protein 90, Blocks Innate and Adaptive Immune Responses in Models of Inflammation and Autoimmunity. The Journal of Immunology. 2011; 186(1): 563-575. doi: 10.4049/jimmunol.1000222
20. Song KH, Oh SJ, Kim S, et al. HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. Nature Communications. 2020; 11(1). doi: 10.1038/s41467-019-14259-y
21. Haggerty TJ, Dunn IS, Rose LB, et al. A Screening Assay to Identify Agents That Enhance T-Cell Recognition of Human Melanomas. ASSAY and Drug Development Technologies. 2012; 10(2): 187-201. doi: 10.1089/adt.2011.0379
22. Zhang YJ, Yi DH. CDK1-SRC Interaction-Dependent Transcriptional Activation of HSP90AB1 Promotes Antitumor Immunity in Hepatocellular Carcinoma. Journal of Proteome Research. 2023; 22(12): 3714-3729. doi: 10.1021/acs.jproteome.3c00379
23. Xiao H, Wang B, Xiong H, et al. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. Journal of Cellular Physiology. 2020; 236(4): 2572-2591. doi: 10.1002/jcp.30015
24. Hutter C, Zenklusen JC. The Cancer Genome Atlas: Creating Lasting Value beyond Its Data. Cell. 2018; 173(2): 283-285. doi: 10.1016/j.cell.2018.03.042
25. Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Research. 2017; 77(21): e108-e110. doi: 10.1158/0008-5472.can-17-0307
26. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005; 102(43): 15545-15550. doi: 10.1073/pnas.0506580102
27. Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Wren J, ed. Bioinformatics. 2019; 35(20): 4200-4202. doi: 10.1093/bioinformatics/btz210
28. von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Research. 2003; 31(1): 258-261. doi: 10.1093/nar/gkg034
29. Wang J, Duncan D, Shi Z, et al. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Research. 2013; 41(W1): W77-W83. doi: 10.1093/nar/gkt439
30. Zhang Y, Ware MB, Zaidi MY, et al. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics. 2021; 20(1): 150-160. doi: 10.1158/1535-7163.mct-19-0911.
31. Griffiths HR, Gao D, Pararasa C. Redox regulation in metabolic programming and inflammation. Redox Biology. 2017; 12: 50-57. doi: 10.1016/j.redox.2017.01.023
32. Raud B, McGuire PJ, Jones RG, et al. Fatty acid metabolism in CD8+ T cell memory: Challenging current concepts. Immunological Reviews. 2018; 283(1): 213-231. doi: 10.1111/imr.12655
33. Vardhana SA, Hwee MA, Berisa M, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nature Immunology. 2020; 21(9): 1022-1033. doi: 10.1038/s41590-020-0725-2
34. Ferrari de Andrade L, Tay RE, Pan D, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018; 359(6383): 1537-1542. doi: 10.1126/science.aao0505
35. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018; 131(1): 39-48. doi: 10.1182/blood-2017-07-741025
Copyright (c) 2024 Yudong Wang
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
